Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Citi
QuintilesIMS
Cipla
McKinsey
Federal Trade Commission
Cantor Fitzgerald
Farmers Insurance
Cerilliant

Generated: October 23, 2017

DrugPatentWatch Database Preview

Teva Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?

TEVA PHARMS has two hundred and sixty-six approved drugs.

There are fifteen US patents protecting TEVA PHARMS drugs and there have been two Paragraph IV challenges on TEVA PHARMS drugs in the past three years. There are thirty-four tentative approvals on TEVA PHARMS drugs.

There are ninety-nine patent family members on TEVA PHARMS drugs in thirty-four countries and three hundred and eighty-one supplementary protection certificates in thirteen countries.

Summary for Applicant: Teva Pharms

International Patents:99
US Patents:15
Tradenames:221
Ingredients:214
NDAs:266
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms
DILTIAZEM HYDROCHLORIDE
diltiazem hydrochloride
TABLET;ORAL074067-001Nov 5, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
METOCLOPRAMIDE HYDROCHLORIDE
metoclopramide hydrochloride
INJECTABLE;INJECTION073135-001Nov 27, 1991APRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
CLARAVIS
isotretinoin
CAPSULE;ORAL076135-003May 11, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
CEFAZOLIN SODIUM
cefazolin sodium
INJECTABLE;INJECTION063016-002Mar 14, 1989DISCNNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
CARBOPLATIN
carboplatin
INJECTABLE;IV (INFUSION)077139-001Sep 21, 2005APRXNoYes► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
AMLODIPINE AND OLMESARTAN MEDOXOMIL
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL091154-001Oct 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
TRANDOLAPRIL
trandolapril
TABLET;ORAL077489-001Dec 12, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
DEXMETHYLPHENIDATE HYDROCHLORIDE
dexmethylphenidate hydrochloride
TABLET;ORAL077107-003Jan 29, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide; losartan potassium
TABLET;ORAL077157-001Apr 6, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
VECURONIUM BROMIDE
vecuronium bromide
INJECTABLE;INJECTION074688-001Aug 25, 1999APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Teva Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TEVA PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
omacetaxine mepesuccinate
for Injection3.5 mg/vial
SYNRIBO
10/26/2016
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
2/26/2014
glatiramer acetate
Injection40 mg/mL, 1 mL pre-filled syringe
COPAXONE
1/29/2014
cyclobenzaprine hydrochloride
Extended-release Capsule15 mg and 30 mg
AMRIX
8/11/2008

Premature patent expirations for TEVA PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Teva Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,245Modified release dosage forms of skeletal muscle relaxants► Subscribe
7,169,774Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
7,842,687Cephalotaxane derivatives and their processes of preparation and purification► Subscribe
6,613,900 Cephalotaxane derivatives and process for their preparation► Subscribe
6,831,180 Cephalotaxane derivatives and process for their preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Teva Pharms Drugs

Country Document Number Estimated Expiration
Japan2009102408► Subscribe
Hungary0101375► Subscribe
Serbia52885► Subscribe
Portugal2177223► Subscribe
Cyprus1112817► Subscribe
South Korea20120090044► Subscribe
Denmark1064285► Subscribe
Australia2002337410► Subscribe
Spain2612001► Subscribe
Australia2002304338► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Teva Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900/01Switzerland► SubscribePRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
2016000104Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
2008000046Germany► SubscribePRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408
00C/032Belgium► SubscribePRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
2016000110Germany► SubscribePRODUCT NAME: KOMBINATION VON RILPIVIRINHYDROCHLORID ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621
C/GB96/057United Kingdom► SubscribePRODUCT NAME: TOPOTECAN; REGISTERED: CH IKS-NR:53857 19961016; UK EU/1/96/027/001 19961112; UK EU/1/96/027/002 19961112
90021Netherlands► SubscribePRODUCT NAME: ZALEPLONUM; REGISTRATION NO/DATE: EU/1/99/099/001 - EU/1/99/099/006, EU/1/99/102/001 - EU/1/99/102/006 19990312
02/005Ireland► SubscribePRODUCT NAME: IMATINIB OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; NAT REGISTRATION NO/DATE: EU/1/01/198/001-006 20011107; FIRST REGISTRATION NO/DATE: CH 55807 55807 01 55807 02 20010621; PAEDIATRIC INVESTIGATION PLAN: P/0028/2012
2014 00050Denmark► SubscribePRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
2012 00035Denmark► SubscribePRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Chinese Patent Office
Boehringer Ingelheim
Dow
McKesson
Cipla
UBS
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot